Literature DB >> 3320922

Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States.

A M McBean1, J F Modlin.   

Abstract

Despite the concerns mentioned in the last section, there are many reasons to believe that a polio immunization schedule that incorporates sequential doses of inactivated poliovirus vaccine and live attenuated poliovirus vaccine would provide both humoral and intestinal immunity to the fully immunized person that is at least as good, if not better, than the immunity achieved by the use of IPV or OPV alone. A substantial degree of protection should also extend to partially immunized and unimmunized preschool aged children in the community. Furthermore most of the cases of OPV-associated paralytic poliomyelitis could be prevented. Because the reasons for these beliefs are based on data from small studies and on inferences from related research, specific recommendations for a change from current polio immunization policy must depend on additional clinical research. Well-designed trials comparing several different options for sequencing both inactivated and live vaccines are needed, and these studies should focus carefully on both humoral and intestinal immunity conferred by the various vaccine schedules.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3320922     DOI: 10.1097/00006454-198710000-00001

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Coverage estimates and patterns of inactivated poliovirus vaccine (IPV) use prior to and during the polio eradication endgame, Jinan City, China, 2010-2015.

Authors:  Caiyun Chang; Ji Zhang; Jingwen Zhou; Ruoming Cao; Kaijun Song; Chong Liu; Xianhui Zhang; Xingyi Geng; Xiaoxue Liu; Chuanbin Li
Journal:  Hum Vaccin Immunother       Date:  2016-07-20       Impact factor: 3.452

2.  A ten-year experience in control of poliomyelitis through a combination of live and killed vaccines in two developing areas.

Authors:  T Tulchinsky; Y Abed; S Shaheen; N Toubassi; Y Sever; M Schoenbaum; R Handsher
Journal:  Am J Public Health       Date:  1989-12       Impact factor: 9.308

Review 3.  Poliomyelitis: present epidemiological situation and vaccination problems.

Authors:  C Mensi; F Pregliasco
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

4.  Seroconversion following killed polio vaccine in neonates.

Authors:  P K Jain; A K Dutta; S Nangia; S Khare; A Saili
Journal:  Indian J Pediatr       Date:  1997 Jul-Aug       Impact factor: 1.967

Review 5.  New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Authors:  Konstantin Chumakov; Ellie Ehrenfeld
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

6.  Application of monoclonal antibody panels in the virological and epidemiological review of poliomyelitis in Poland, 1981-1990.

Authors:  Z Jarzabek; J Zabicka; A John; J Howlett; G Dunn; D J Wood
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

7.  Acquisition of immunity in mothers of infants administered trivalent oral poliovirus vaccine.

Authors:  R Dagan; D Fraser; R Handsher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-12       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.